|
1
|
Wai PY and Kuo PC: Osteopontin: regulation
in tumor metastasis. Cancer Metastasis Rev. 27:103–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khan SA, Lopez-Chua CA, Zhang J, Fisher
LW, Sørensen ES and Denhardt DT: Soluble osteopontin inhibits
apoptosis of adherent endothelial cells deprived of growth factors.
J Cell Biochem. 85:728–736. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Frenzel A, Grespi F, Chmelewskij W and
Villunger A: Bcl2 family proteins in carcinogenesis and the
treatment of cancer. Apoptosis. 14:584–596. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoo SH, Yoon YG, Lee JS, et al: Etoposide
induces a mixed type of programmed cell death and overcomes the
resistance conferred by Bcl-2 in Hep3B hepatoma cells. Int J Oncol.
41:1443–1454. 2012.PubMed/NCBI
|
|
5
|
Spampanato C, De Maria S, Sarnataro M, et
al: Simvastatin inhibits cancer cell growth by inducing apoptosis
correlated to activation of Bax and downregulation of BCL-2 gene
expression. Int J Oncol. 40:935–941. 2012.PubMed/NCBI
|
|
6
|
Callagy GM, Pharoah PD, Pinder SE, et al:
Bcl-2 is a prognostic marker in breast cancer independently of the
Nottingham Prognostic Index. Clin Cancer Res. 12:2468–2475. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dawson SJ, Makretsov N, Blows FM, et al:
BCL2 in breast cancer: a favourable prognostic marker across
molecular subtypes and independent of adjuvant therapy received. Br
J Cancer. 103:668–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hung JH, Teng YN, Wang LH, et al:
Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant
large surface protein resistance to 5-fluorouracil treatment in
Huh-7 cells. PLoS One. 6:e289772011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao J, Dong L, Lu B, et al:
Down-regulation of osteopontin suppresses growth and metastasis of
hepatocellular carcinoma via induction of apoptosis.
Gastroenterology. 135:956–968. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu XD, Zhang JB, Zhuang PY, et al: High
expression of macrophage colony-stimulating factor in peritumoral
liver tissue is associated with poor survival after curative
resection of hepatocellular carcinoma. J Clin Oncol. 26:2707–2716.
2008. View Article : Google Scholar
|
|
11
|
Llovet JM, Di Bisceglie AM, Bruix J, et
al: Design and endpoints of clinical trials in hepatocellular
carcinoma. J Natl Cancer Inst. 100:698–711. 2008. View Article : Google Scholar
|
|
12
|
Huang H, Zhang XF, Zhou HJ, et al:
Expression and prognostic significance of osteopontin and caspase-3
in hepatocellular carcinoma patients after curative resection.
Cancer Sci. 101:1314–1319. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao Q, Qiu SJ, Fan J, et al: Intratumoral
balance of regulatory and cytotoxic T cells is associated with
prognosis of hepatocellular carcinoma after resection. J Clin
Oncol. 25:2586–2593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding ZB, Shi YH, Zhou J, et al:
Association of autophagy defect with a malignant phenotype and poor
prognosis of hepatocellular carcinoma. Cancer Res. 68:9167–9175.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Butler WT and Ritchie H: The nature and
functional significance of dentin extracellular matrix proteins.
Int J Dev Biol. 39:169–179. 1995.PubMed/NCBI
|
|
16
|
Coppola D, Szabo M, Boulware D, et al:
Correlation of osteopontin protein expression and pathological
stage across a wide variety of tumor histologies. Clin Cancer Res.
10:184–190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rittling SR and Chambers AF: Role of
osteopontin in tumour progression. Br J Cancer. 90:1877–1881. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singhal H, Bautista DS, Tonkin KS, et al:
Elevated plasma osteopontin in metastatic breast cancer associated
with increased tumor burden and decreased survival. Clin Cancer
Res. 3:605–611. 1997.PubMed/NCBI
|
|
19
|
Fedarko NS, Jain A, Karadag A, Van Eman MR
and Fisher LW: Elevated serum bone sialoprotein and osteopontin in
colon, breast, prostate, and lung cancer. Clin Cancer Res.
7:4060–4066. 2001.PubMed/NCBI
|
|
20
|
Hotte SJ, Winquist EW, Stitt L, Wilson SM
and Chambers AF: Plasma osteopontin: associations with survival and
metastasis to bone in men with hormone-refractory prostate
carcinoma. Cancer. 95:506–512. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pan HW, Ou YH, Peng SY, et al:
Overexpression of osteopontin is associated with intrahepatic
metastasis, early recurrence, and poorer prognosis of surgically
resected hepatocellular carcinoma. Cancer. 98:119–127. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ye QH, Qin LX, Forgues M, et al:
Predicting hepatitis B virus-positive metastatic hepatocellular
carcinomas using gene expression profiling and supervised machine
learning. Nat Med. 9:416–423. 2003. View
Article : Google Scholar
|
|
23
|
Sun J, Xu HM, Zhou HJ, et al: The
prognostic significance of preoperative plasma levels of
osteopontin in patients with TNM stage-I of hepatocellular
carcinoma. J Cancer Res Clin Oncol. 136:1–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang H, Ye QH, Ren N, et al: The
prognostic significance of preoperative plasma levels of
osteopontin in patients with hepatocellular carcinoma. J Cancer Res
Clin Oncol. 132:709–717. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yan W, Qian C, Zhao P, et al: Expression
pattern of osteopontin splice variants and its functions on cell
apoptosis and invasion in glioma cells. Neuro Oncol. 12:765–775.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie H, Song J, Du R, et al: Prognostic
significance of osteopontin in hepatitis B virus-related
hepatocellular carcinoma. Dig Liver Dis. 39:167–172. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fesik SW: Promoting apoptosis as a
strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cory S, Huang DC and Adams JM: The Bcl-2
family: roles in cell survival and oncogenesis. Oncogene.
22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tanaka S, Louie D, Kant J and Reed JC:
Application of a PCR-mismatch technique to the BCL-2 gene:
detection of point mutations in BCL-2 genes of malignancies with A
t(14,18). Leukemia. 6(Suppl 3): S15–S19. 1992.PubMed/NCBI
|
|
30
|
Cheng EH, Kirsch DG, Clem RJ, et al:
Conversion of Bcl-2 to a Bax-like death effector by caspases.
Science. 278:1966–1968. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin YP, Zhu BZ, Yang MC, et al: Bcl-2
overexpression inhibits tetrachlorohydroquinone-induced apoptosis
in NIH3T3 cells: a possible mechanism for tumor promotion. Mol
Carcinog. 40:24–33. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bivona TG, Quatela SE, Bodemann BO, et al:
PKC regulates a farnesyl-electrostatic switch on K-Ras that
promotes its association with Bcl-XL on mitochondria and induces
apoptosis. Mol Cell. 21:481–493. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schwartz PS and Hockenbery DM: Targeted
therapies for epithelial cancers: in vivo efficacy of the
BCL-2/BCL-XL inhibitor 2-MeAA. Cancer Biol Ther. 6:465–466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Silvestrini R, Veneroni S, Daidone MG, et
al: The Bcl-2 protein: a prognostic indicator strongly related to
p53 protein in lymph node-negative breast cancer patients. J Natl
Cancer Inst. 86:499–504. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsamandas AC, Thomopoulos K, Gogos C, et
al: Expresssion of bcl-2 oprotein in cases of acute and chronic
viral hepatitis type B and type C: a clinicopathologic study. Dig
Dis Sci. 47:1618–1624. 2002. View Article : Google Scholar : PubMed/NCBI
|
